Search Results - "Rajamani, Bharathi M"

Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2 by Karathedath, Sreeja, Rajamani, Bharathi M, Musheer Aalam, Syed Mohammed, Abraham, Ajay, Varatharajan, Savitha, Krishnamurthy, Partha, Mathews, Vikram, Velayudhan, Shaji Ramachandran, Balasubramanian, Poonkuzhali

“…Cytarabine (Ara-C) and Daunorubicin (Dnr) forms the backbone of acute myeloid leukemia (AML) therapy. Drug resistance and toxic side effects pose a major…”
Get full text

Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo by Rajamani, Bharathi M, Illangeswaran, Raveen Stephen Stallon, Benjamin, Esther Sathya Bama, Balakrishnan, Balaji, Jebanesan, Daniel Zechariah Paul, Das, Saswati, Pai, Aswin Anand, Vidhyadharan, Rakhi Thalayattu, Mohan, Ajith, Karathedath, Sreeja, Abraham, Aby, Mathews, Vikram, Velayudhan, Shaji R, Balasubramanian, Poonkuzhali

“…The ligand-activated transcription factors, nuclear hormone receptors (NHRs), remain unexplored in hematological malignancies except for retinoic acid receptor…”
Get full text

Prognostic plasma biomarkers of early complications and graft‐versus‐host disease in patients undergoing allogeneic hematopoietic stem cell transplantation by Balakrishnan, Balaji, Illangeswaran, Raveen Stephen Stallon, Rajamani, Bharathi M, Pai, Aswin Anand, Raj, Infencia Xavier, Paul, Daniel Zechariah, Lakshmi, Kavitha, Mani, Thenmozhi, Mohanan, Ezhilpavai, Kulkarni, Uday, Devasia, Anup Joseph, NA, Fouzia, Korula, Anu, Abraham, Aby, Srivastava, Alok, Mathews, Vikram, Paczesny, Sophie, George, Biju, Balasubramanian, Poonkuzhali

“…Early complications post hematopoietic stem cell transplantation (HSCT) such as sinusoidal obstruction syndrome (SOS) and graft versus host disease (GVHD) can…”
Get full text

Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines by Illangeswaran, Raveen Stephen Stallon, Jebanesan, Daniel Zechariah Paul, Sivakumar, Kezia Kanimozhi, Vidhyadharan, Rakhi Thalayattu, Rajamani, Bharathi M., Janet, Nancy Beryl, David, Ernest, Velayudhan, Shaji Ramachandran, Mathews, Vikram, Balasubramanian, Poonkuzhali

“…Chemotherapy resistance leading to disease relapse is a significant barrier in treating acute myeloid leukemia (AML). Metabolic adaptations have been shown to…”
Get full text

Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia by Jebanesan, Daniel Zechariah Paul, Illangeswaran, Raveen Stephen Stallon, Rajamani, Bharathi M., Vidhyadharan, Rakhi Thalayattu, Das, Saswati, Bijukumar, Nayanthara K., Balakrishnan, Balaji, Mathews, Vikram, Velayudhan, Shaji R., Balasubramanian, Poonkuzhali

“…De novo acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) have worse treatment outcomes. Arsenic…”
Get full text

Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSCs) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs by Benjamin, Esther Sathya Bama, Vinod, Elizabeth, Illangeswaran, Raveen Stephen Stallon, Rajamani, Bharathi M., Vidhyadharan, Rakhi Thalayattu, Bagchi, Abhirup, Maity, Arnab, Mohan, Ajith, Parasuraman, Ganesh, Amirtham, Soosai Manickam, Abraham, Aby, Velayudhan, Shaji R, Balasubramanian, Poonkuzhali

“…Despite the success of Tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML), leukemic stem cells (LSCs) persist, contributing to…”
Get full text

Corrigendum to “Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines” [Leukemia Res. 128, 107054] by Illangeswaran, Raveen Stephen Stallon, Jebanesan, Daniel Zechariah Paul, Sivakumar, Kezia Kanimozhi, Vidhyadharan, Rakhi Thalayattu, Rajamani, Bharathi M., Janet, Nancy Beryl, David, Ernest, Velayudhan, Shaji Ramachandran, Mathews, Vikram, Balasubramanian, Poonkuzhali

Get full text

Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients by Rajamani, Bharathi M., Benjamin, Esther Sathya Bama, Abraham, Aby, Ganesan, Sukanya, Lakshmi, Kavitha M., Anandan, Senthamizhselvi, Karathedath, Sreeja, Varatharajan, Savitha, Mohanan, Ezhilpavai, Janet, Nancy Beryl, Srivastava, Vivi M., Ramachandran Velayudhan, Shaji, Kulkarni, Uday P., Devasia, Anup J., Fouzia, N. A., Korula, Anu, George, Biju, Srivastava, Alok, Mathews, Vikram, Balasubramanian, Poonkuzhali

“…Achieving early molecular response (EMR) has been shown to be associated with better event free survival in patients with chronic phase chronic myeloid…”
Get full text

Genetic Ablation of Nuclear Receptor Interacting Protein 1 (NRIP1) Sensitizes Acute Myeloid Leukemia Cells to Retinoic Acids by Illangeswaran, Raveen Stephen Stallon, Karathedath, Sreeja, Bagchi, Abhirup, Rajamani, Bharathi M, Balakrishnan, Balaji, Mathews, Vikram, Velayudhan, Shaji Ramachandran, Balasubramanian, Poonkuzhali

“…The success of differentiation therapy is limited to acute promyelocytic leukemia (APL), and approaches to overcome the differentiation block in non-M3 AML…”
Get full text

Rxra Overexpression Improves the Sensitivity to Imatinib I n-Vitro/in-Vivo By Disrupting the Oxidative Capacity of Chronic Myeloid Leukemia Cells by Illangeswaran, Raveen Stephen Stallon, Rajamani, Bharathi M, Benjamin, Esther Sathya Bama, Das, Saswati, Jebanesan, Daniel Zechariah Paul, Mathews, Vikram, Velayudhan, Shaji Ramachandran, Balasubramanian, Poonkuzhali

Get full text

Rxra Overexpression Improves the Sensitivity to Imatinib In-Vitro/in-Vivo By Disrupting the Oxidative Capacity of Chronic Myeloid Leukemia Cells by Illangeswaran, Raveen Stephen Stallon, Rajamani, Bharathi M, Benjamin, Esther Sathya Bama, Das, Saswati, Jebanesan, Daniel Zechariah Paul, Mathews, Vikram, Velayudhan, Shaji Ramachandran, Balasubramanian, Poonkuzhali

Get full text

Global Gene Expression Analysis Reveals Genotoxic Effect of Nrf2 Pharmacological Inhibitor Brusatol in Myeloid Leukemia Cells- a Promising Novel Anticancer Agent by Illangeswaran, Raveen Stephen Stallon, Karathedath, Sreeja, Rajamani, Bharathi M, Balasubramanian, Poonkuzhali

“…Combating drug resistance is a paramount task in treating acute myeloid leukemia (AML). NFE2 related factor 2 (NRF2) is a major player in inducing chemo…”
Get full text

Abstract 3739: Nuclear hormone receptors modulate imatinib resistance in chronic myeloid leukemia (CML) by Rajamani, Bharathi M., Karathedath, Sreeja, Illangeswaran, Raveen Stephen, Benjamin, Esther Sathya Bama, Mathews, Vikram, Abraham, Aby, Balasubramanian, Poonkuzhali

“…Abstract Despite the impressive success of molecular targeted therapy in chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI) such as imatinib…”
Get full text

Role of NF-E2 Related Factor 2 (NRF2) on Chemotherapy Resistance in Acute Myeloid Leukemia (AML) and the Effect of Pharmacological Inhibition of NRF2 by Karathedath, Sreeja, Rajamani, Bharathi M, Varatharajan, Savitha, Abraham, Ajay, Mathews, Vikram, Velayudhan, Shaji R, Balasubramanian, Poonkuzhali

“…Although 70-80% of Acute Myeloid Leukemia (AML) patients achieve complete remission with the induction therapy consisting of a combination of Cytarabine…”
Get full text

Molecular and Pharmacological Inhibition of ATP Binding Cassette Transporter ABCB6 Decreases Chemoresistance in Acute Myeloid Leukemia by Karathedath, Sreeja, Illangeswaran, Raveen Stephen Stallon, Das, Saswati, Rajamani, Bharathi M, Marepally, Srujan Kumar, Kasturi, Partha, Mathews, Vikram, Velayudhan, Shaji Ramachandran, Balasubramanian, Poonkuzhali

“…Cytarabine (Ara-C) and Daunorubicin (Dnr) remain the main stay treatment for patients with acute myeloid leukemia (AML). Drug resistance and relapse are the…”
Get full text

Role of NF-E2 related factor 2 by Karathedath, Sreeja, Rajamani, Bharathi M, Musheer Aalam, Syed Mohammed, Abraham, Ajay, Varatharajan, Savitha, Krishnamurthy, Partha, Mathews, Vikram, Velayudhan, Shaji Ramachandran, Balasubramanian, Poonkuzhali

“…Cytarabine (Ara-C) and Daunorubicin (Dnr) forms the backbone of acute myeloid leukemia (AML) therapy. Drug resistance and toxic side effects pose a major…”
Get full text

Role of NF-E2 related factor 2 and the effect of pharmacological inhibition of Nrf2 by Karathedath, Sreeja, Rajamani, Bharathi M, Musheer Aalam, Syed Mohammed, Abraham, Ajay, Varatharajan, Savitha, Krishnamurthy, Partha, Mathews, Vikram, Velayudhan, Shaji Ramachandran, Balasubramanian, Poonkuzhali

“…Cytarabine (Ara-C) and Daunorubicin (Dnr) forms the backbone of acute myeloid leukemia (AML) therapy. Drug resistance and toxic side effects pose a major…”
Get full text

Abstract 3977: Pharmacological inhibition of Nrf2 overcomes acquired resistance to arsenic trioxide in FLT3 mutated acute myeloid leukemia by Jebanesan, Daniel Zechariah, Illangeswaran, Raveen Stephen, Das, Saswati, Vidhyadharan, Rakhi Thalayattu, Bijukumar, Nayanthara Karpillymoola, Rajamani, Bharathi M., Balakrishnan, Balaji, Mathews, Vikram, Velayudhan, Shaji Ramachandran, Balasubramanian, Poonkuzhali

“…Abstract De novo acute myeloid leukemia (AML) patients with fms-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) have worse treatment outcomes…”
Get full text

Expression Profiling Of Nuclear Hormone Receptors In Myeloid Leukemia Reveals Potential Novel Drug Targets For Combination Therapy by Karathedath, Sreeja, Ganesan, Sukanya, Zhang, Wei, Abraham, Ajay, Varatharajan, Savitha, Rajamani, Bharathi M, Velayudhan, Shaji R, Srivastava, Alok, Mathews, Vikram, Balasubramanian, Poonkuzhali

“…Nuclear Hormone Receptors (NHRs) are a large superfamily of ligand dependent transcription factors regulating a plethora of genes involved in metabolism,…”
Get full text